The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
COVID-19 vaccines: rapid development, implications, challenges and future prospects
Open accessAbstract
COVID-19 has affected millions of people and put an unparalleled burden on healthcare systems as well as economies throughout the world. Currently, there is no decisive therapy for COVID-19 or related complications. The only hope to mitigate this pandemic is through vaccines. The COVID-19 vaccines are being developed rapidly, compared to traditional vaccines, and are being approved via Emergency Use Authorization (EUA) worldwide. So far, there are 232 vaccine candidates. One hundred and seventy-two are in preclinical development and 60 in clinical development, of which 9 are approved under EUA by different countries. This includes the United Kingdom (UK), United States of America (USA), Canada, Russia, China, and India. Distributing vaccination to all, with a safe and efficacious vaccine is the leading priority for all nations to combat this COVID-19 pandemic. However, the current accelerated process of COVID-19 vaccine development and EUA has many unanswered questions. In addition, the change in strain of SARS-CoV-2 in UK and South Africa, and its increasing spread across the world have raised more challenges, both for the vaccine developers as well as the governments across the world. In this review, we have discussed the different type of vaccines with examples of COVID-19 vaccines, their rapid development compared to the traditional vaccine, associated challenges, and future prospects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccine hesitancy: Definition, scope and determinants
MacDonald, N. E. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.036 · Cited by 5,573 · cited 2×
“It is affected by factors such as complacency, convenience, and confidence [74].”
BackgroundAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406 · cited 1×
“Neutralizing antibody titers of these participants were similar to the convalescent sera from COVID-19 recuperated patients [21].”
ResultOu, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · cited 2×
“The results demonstrated an acceptable safety profile for ChAdOx1 nCoV19 and increased antibody response by homologous boosting [30].”
BackgroundSARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · cited 10×
“Therefore, the first clinical trial of CVCs started in March 2020 (NCT04283461) [11].”
BackgroundMethodInfluentialSARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156
Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G. F., Tan, W., Wu, G., Xu, M., Lou, Z., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30831-8 · Cited by 1,144
Reiter, P. L., Pennell, M. L., & Katz, M. L. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.08.043 · Cited by 1,103
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914
COVID-19 Vaccine: A comprehensive status report
Kaur, S. P., & Gupta, V. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198114 · Cited by 852
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789
Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy
Sridhar, S., Luedtke, A., Langevin, E., Zhu, M., Bonaparte, M., Machabert, T., Savarino, S., Zambrano, B., Moureau, A., Khromava, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800820 · Cited by 783
Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., et al. (2020) · JAMA · doi:10.1001/jama.2020.15543 · Cited by 759
Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19
Sharma, O., Sultan, A. A., Ding, H., & Triggle, C. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585354 · Cited by 546
Manipulation of the Innate Immune Response by Varicella Zoster Virus
Gerada, C., Campbell, T. M., Kennedy, J. J., McSharry, B. P., Steain, M., Slobedman, B., & Abendroth, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00001 · Cited by 354
Bartsch, S. M., O'Shea, K. J., Ferguson, M. C., Bottazzi, M. E., Wedlock, P. T., Strych, U., McKinnell, J. A., Siegmund, S. S., Cox, S. N., Hotez, P. J., et al. (2020) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2020.06.011 · Cited by 324
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Tostanoski, L. H., Wegmann, F., Martinot, A. J., Loos, C., McMahan, K., Mercado, N. B., Yu, J., Chan, C. N., Bondoc, S., Starke, C. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1070-6 · Cited by 286
Vaccine impact: Benefits for human health
Doherty, M., Buchy, P., Standaert, B., Giaquinto, C., & Prado- Cohrs, D. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.025 · Cited by 272
Four decades of HIV/AIDS - much accomplished, much to do
Fauci, A. S., & Lane, H. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmp1916753 · Cited by 199
Krubiner, C. B., Faden, R. R., Karron, R. A., Little, M. O., Lyerly, A. D., Abramson, J. S., Beigi, R. H., Cravioto, A. R., Durbin, A. P., Gellin, B. G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2019.01.011 · Cited by 169
Contingent assessment of the COVID-19 vaccine
García, L. Y., & Cerda, A. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.068 · Cited by 156
Graham, S. P., McLean, R. K., Spencer, A. J., Belij‐Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J. C., Hayes, J. W. P., Martini, V., Thakur, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00221-3 · Cited by 152
Vaccine development: From concept to early clinical testing
Cunningham, A. L., Garçon, N., Léo, O., Friedland, L. R., Strugnell, R. A., Laupèze, B., Doherty, M. T., & Stern, P. L. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.016 · Cited by 151
Khuroo, M. S. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106101 · Cited by 131
SARS-CoV-2 Vaccine Development: Current Status
Poland, G. A., Ovsyannikova, I. G., Crooke, S. N., & Kennedy, R. B. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.021 · Cited by 125
Yadav, P. D., Ella, R., Kumar, S., Patil, D., Mohandas, S., Shete, A. M., Vadrevu, K. M., Bhati, G., Sapkal, G. N., Kaushal, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21639-w · Cited by 114
Jouneau, L., Lefebvre, D. J., Costa, F., Romey, A., Blaise‐Boisseau, S., Relmy, A., Jaszczyszyn, Y., Dard-Dascot, C., Dejean, S., Versillé, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-019-0151-3 · Cited by 104
COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Khuroo, M. S., Khuroo, M. S., Khuroo, M. S., Sofi, A. A., & Khuroo, N. S. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.06.003 · Cited by 99
Holm, M. R., & Poland, G. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.12.017 · Cited by 89
Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective
Gupta, A., Kashte, S., Gupta, M., Rodriguez, H. C., Gautam, S. S., & Kadam, S. S. (2020) · Human Cell · doi:10.1007/s13577-020-00407-w · Cited by 83
Self-citationCoronavirus disease 2019 vaccines in pregnancy
Craig, A. M., Hughes, B. L., & Swamy, G. K. (2020) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2020.100295 · Cited by 71
Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply
Pagliusi, S. R., Jarrett, S., Hayman, B., Kreysa, U., Prasad, S. D., Reers, M., Thai, P. H., Wu, K., Zhang, Y. T., Baek, Y. O., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.06.022 · Cited by 60
City, P. S. M. M. (2021) · Saudi Medical Journal · doi:10.15537/1658-3175.7682 · Cited by 30
Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives
Hwang, A., Veira, C. L., Malvolti, S., Cherian, T. P., MacDonald, N. E., Steffen, C. A., Jones, I., Hinman, A. R., & Mantel, C. F. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.048 · Cited by 22
COVID-19 Vaccines in Pregnancy
Vlădăreanu, R. (2021) · Ginecologia ro · Cited by 7
Cited by
The Health Belief Model Applied to COVID-19 Vaccine Hesitancy: A Systematic Review
Limbu, Y. B., Gautam, R. K., & Pham, L. (2022) · Vaccines · doi:10.3390/vaccines10060973 · Cited by 271
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Lipopeptides for Vaccine Development
Hamley, I. W. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00258 · Cited by 62
Toyama, K., Eto, T., Takazawa, K., Shimizu, S., Nakayama, T., Furihata, K., Sogawa, Y., Kumazaki, M., Jonai, N., Matsunaga, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.012 · Cited by 18
Metadata
- Authors
- Kashte, S., Gulbake, A., El-Amin III, S. F., & Gupta, A.
- Venue
- Human Cell
- Published
- 2021-03-07
- Volume
- 34
- Issue
- 3
- Pages
- 711-733
- ISSN
- 0914-7470 (ISSN-L)
- 1749-0774
- OpenAlex
- W3134914607
- Cited by
- 402
- References
- 46
- FWCI
- 25.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.